AdoraPet Biosciences
About this raise
AdoraPet Biosciences, with a valuation of $20 million, is raising funds on DealMaker Securities. The company’s goal is to allow pets and owners to spend more time together by using state-of-the-art gene technology to eliminate the genes that cause allergies in owners and diseases in our pets. CRISPR is a Nobel Prize-winning technology scientists can use to remove problem-causing genes. AdoraPet plans to use CRISPR technology to modify these genes in embryos, creating allergy-free, long-living pets for everyone. Dr. Richard Chin, Dr. Stephen Sundlof and Dr. George Church founded AdoraPet in 2022. The current crowdfunding campaign has a minimum target of $50,000 and a maximum target of $5,000,000.
Investment Overview
Not Funded: $0
Deal Terms
Total Commitments
- Platform
- DealMaker Securities
- Start Date
- 12/19/2022
- Close Date
- 04/10/2023
$50,000
$5,000,000
$1,000
Equity - Common
Early Stage
RegCF
$5.00
$35,000,000
Company & Team
Company
- Year Founded
- 2022
- Industry
- Pet Health, Food, and Services
- Tech Sector
- Distribution Model
- B2B
- Margin
- Low
- Capital Intensity
- High
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $0
- VC Backed?
- No
| Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|
| 04/10/2023 | DealMaker Securities | $35,000,000 | $0 | Equity - Common | Not Funded | RegCF |
